Karen Bufford, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 487 Cedar River Dr, Fowlerville, MI 48836 Phone: 734-218-5656 |
News Archive
Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea's unique and proprietary antigen discovery technology. The combination of Genocea's novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21").
Luminescent markers are an indispensable tool for researchers working with DNA. But the markers are troublesome. Some tend to destroy the function and structure of DNA when inserted. Others emit so little light, that they can barely be detected in the hereditary material. So researchers have been asking for alternative markers.
A new computational method developed by scientists from the University of Chicago improves the detection of genes that are likely to be causal for complex diseases and biological traits. The method, PrediXcan, estimates gene expression levels across the whole genome - a better measure of biological action than single mutations - and integrates it with genome-wide association study (GWAS) data.
› Verified 9 days ago